Darling Ingredients (DAR) Introduces Nextida GC

Darling Ingredients Inc. (NYSE: DAR) today announced that it has launched Nextida™ GC, a new collagen peptide that displayed a reduction in the post-meal glucose spike in healthy individuals. The clinical trial¹, conducted by Darling Ingredients' premier collagen and gelatin brand Rousselot, showed that a 5-gram or 10-gram dose orally 30 minutes before a meal significantly lowered post-meal glucose spike in the blood by an average of 42%².

"Darling Ingredients has unlocked the next wave of collagen-based solutions that are truly revolutionary. Produced through our proprietary process, we have discovered a way to use natural collagen for targeted health benefits," said Randall C. Stuewe, Chairman and CEO.

Nextida GC is the first of many collagen-based solutions with targeted health benefits that the company is developing.

"Our scientific work continues to demonstrate how collagen can effectively be used to target common health and wellness benefits," Stuewe said. "Built on science with patents pending, we continue to unveil the power of collagen to help us live happy, healthier lives."

You May Also Be Interested In

• Darling Ingredients (DAR) PT Lowered to $70 at TD Cowen
• Fiserv tender offer draws $1.33B in notes by expiration
• Rockstar Games opens GTA VI pre-orders, priced at $79.99